The systems are intended for single patient use and require a prescription.ĬONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.Ĭonnect with us at on Facebook at and on Twitter and and Important Safety InformationįreeStyle Libre and FreeStyle Libre 14 day Flash Glucose Monitoring systems are continuous glucose monitoring (CGM) devices indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life.
#Freestyle libre flash glucose monitoring system sensor full#
Additionally, Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 30 countries, including France, Japan, the United Kingdom and the U.S.įor more information, please visit: About AbbottĪt Abbott, we're committed to helping people live their best possible life through the power of health.
The FreeStyle Libre 14 day system will be available via prescription in the coming months at participating pharmacies and durable medical equipment suppliers (DMEs) in the U.S.įreeStyle Libre system is now being used by more than 800,000 people across more than 43 countries 8 and is the #1 CGM worldwide 9. The FreeStyle Libre system (10 day) was approved by the FDA in September 2017. The FreeStyle Libre 14 day system has a 1-hour warmup and greater accuracy compared to the FreeStyle Libre system (10 day) with a mean absolute relative difference (MARD) of 9.4 compared to 9.7, respectively. The FreeStyle Libre system is supported by both clinical data 5,6 and real-world evidence 7 that show that people who scan more frequently spend less time in hypoglycemia (low-glucose levels) or hyperglycemia (high-glucose levels) while having improved average glucose levels, demonstrating improved glucose control overall. The sensor is worn on the back of the upper arm and is the size of two stacked quarters. With just a quick, one-second scan, users can see real-time glucose readings, as well as identify glucose trends with a directional arrow and review eight hours of glucose history. In the U.S., the FreeStyle Libre system (10 day) is approved for replacement 2 of blood glucose monitoring (BGM) for adults with diabetes.
The FreeStyle Libre system, which first launched in Europe in 2014, with a 14-day wear time, was the first to eliminate the need for fingersticks 10, and is designed to be an easier-to-use 2, streamlined 3 and more affordable system 4 compared with other available CGMs on the market. "With the new FreeStyle Libre 14 day system, people with diabetes will now have extended access to their glucose data with a high degree of accuracy, which will improve their experience and help empower them to better manage their condition." "At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. This approval makes Abbott's revolutionary continuous glucose monitor (CGM) the longest lasting self-applied personal glucose sensor available on the market. Food and Drug Administration (FDA) has approved the FreeStyle ® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. ABBOTT PARK, Ill., J/PRNewswire/ - Abbott ( NYSE: ABT) today announced that the U.S.
0 kommentar(er)
